文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

组成性激活的ALK2和增加的SMAD1/5协同诱导进行性骨化性纤维发育不良中的骨形态发生蛋白信号传导。

Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.

作者信息

Fukuda Toru, Kohda Masakazu, Kanomata Kazuhiro, Nojima Junya, Nakamura Atsushi, Kamizono Jyunji, Noguchi Yasuo, Iwakiri Kiyofumi, Kondo Takeo, Kurose Junichi, Endo Ken-ichi, Awakura Takeshi, Fukushi Junichi, Nakashima Yasuharu, Chiyonobu Tomohiro, Kawara Akira, Nishida Yoshihiro, Wada Ikuo, Akita Masumi, Komori Tetsuo, Nakayama Konosuke, Nanba Akira, Maruki Yuichi, Yoda Tetsuya, Tomoda Hiroshi, Yu Paul B, Shore Eileen M, Kaplan Frederick S, Miyazono Kohei, Matsuoka Masaru, Ikebuchi Kenji, Ohtake Akira, Oda Hiromi, Jimi Eijiro, Owan Ichiro, Okazaki Yasushi, Katagiri Takenobu

机构信息

Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama 350-1241, Japan.

出版信息

J Biol Chem. 2009 Mar 13;284(11):7149-56. doi: 10.1074/jbc.M801681200. Epub 2008 Aug 6.


DOI:10.1074/jbc.M801681200
PMID:18684712
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2652274/
Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by congenital malformation of the great toes and by progressive heterotopic bone formation in muscle tissue. Recently, a mutation involving a single amino acid substitution in a bone morphogenetic protein (BMP) type I receptor, ALK2, was identified in patients with FOP. We report here that the identical mutation, R206H, was observed in 19 Japanese patients with sporadic FOP. This mutant receptor, ALK2(R206H), activates BMP signaling without ligand binding. Moreover, expression of Smad1 and Smad5 was up-regulated in response to muscular injury. ALK2(R206H) with Smad1 or Smad5 induced osteoblastic differentiation that could be inhibited by Smad7 or dorsomorphin. Taken together, these findings suggest that the heterotopic bone formation in FOP may be induced by a constitutively activated BMP receptor signaling through Smad1 or Smad5. Gene transfer of Smad7 or inhibition of type I receptors with dorsomorphin may represent strategies for blocking the activity induced by ALK2(R206H) in FOP.

摘要

进行性骨化性纤维发育不良(FOP)是一种罕见的常染色体显性疾病,其特征为大脚趾先天性畸形以及肌肉组织中进行性异位骨形成。最近,在FOP患者中发现了一种涉及骨形态发生蛋白(BMP)I型受体ALK2中单个氨基酸替代的突变。我们在此报告,在19例日本散发性FOP患者中观察到了相同的突变R206H。这种突变受体ALK2(R206H)在没有配体结合的情况下激活BMP信号传导。此外,响应肌肉损伤,Smad1和Smad5的表达上调。带有Smad1或Smad5的ALK2(R206H)诱导成骨细胞分化,而这种分化可被Smad7或多效唑抑制。综上所述,这些发现表明FOP中的异位骨形成可能是由通过Smad1或Smad5的组成型激活的BMP受体信号传导诱导的。Smad7的基因转移或用多效唑抑制I型受体可能代表了阻断ALK2(R206H)在FOP中诱导的活性的策略。

相似文献

[1]
Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.

J Biol Chem. 2009-3-13

[2]
ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.

J Bone Miner Res. 2010-6

[3]
A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor.

Biochem Biophys Res Commun. 2008-12-19

[4]
The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.

Stem Cell Res Ther. 2016-8-17

[5]
A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.

Biochem Biophys Res Commun. 2011-3-4

[6]
Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.

Mol Endocrinol. 2015-1

[7]
Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.

Stem Cells. 2014-5

[8]
Dysregulated BMP signaling through ACVR1 impairs digit joint development in fibrodysplasia ossificans progressiva (FOP).

Dev Biol. 2021-2

[9]
Role of matrix metalloproteinase-10 in the BMP-2 inducing osteoblastic differentiation.

Endocr J. 2013-9-28

[10]
Activation of G signaling by Pasteurella multocida toxin inhibits the osteoblastogenic-like actions of Activin A in C2C12 myoblasts, a cell model of fibrodysplasia ossificans progressiva.

Bone. 2019-7-31

引用本文的文献

[1]
Signaling Dynamics in Osteogenesis: Unraveling Therapeutic Targets for Bone Generation.

Curr Drug Targets. 2025

[2]
HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity.

Nat Rev Rheumatol. 2025-2

[3]
Molecular Developmental Biology of Fibrodysplasia Ossificans Progressiva: Measuring the Giant by Its Toe.

Biomolecules. 2024-8-15

[4]
Fibrodysplasia ossificans progressiva: Two case reports.

Radiol Case Rep. 2024-5-3

[5]
Cellular and Molecular Mechanisms of Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva.

Biomedicines. 2024-4-2

[6]
BRCC3 Regulation of ALK2 in Vascular Smooth Muscle Cells: Implication in Pulmonary Hypertension.

Circulation. 2024-7-9

[7]
The HIF-1α and mTOR Pathways Amplify Heterotopic Ossification.

Biomolecules. 2024-1-24

[8]
The Activation of the Fibrodysplasia Ossificans Progressiva-Inducing ALK2-R206H Mutant Depends on the Distinct Homo-Oligomerization Patterns of ACVR2B and ACVR2A.

Cells. 2024-1-25

[9]
How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva.

Biomolecules. 2024-1-12

[10]
Navigating the Complex Landscape of Fibrodysplasia Ossificans Progressiva: From Current Paradigms to Therapeutic Frontiers.

Genes (Basel). 2023-11-30

本文引用的文献

[1]
Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP).

J Bone Miner Metab. 2008

[2]
Bone morphogenetic protein-9 is a circulating vascular quiescence factor.

Circ Res. 2008-4-25

[3]
Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism.

Nat Chem Biol. 2008-1

[4]
Selective inhibitory effects of Smad6 on bone morphogenetic protein type I receptors.

J Biol Chem. 2007-7-13

[5]
The ACVR1 617G>A mutation is also recurrent in three Japanese patients with fibrodysplasia ossificans progressiva.

J Hum Genet. 2007

[6]
Hematopoietic stem-cell contribution to ectopic skeletogenesis.

J Bone Joint Surg Am. 2007-2

[7]
Dysregulation of the BMP-4 signaling pathway in fibrodysplasia ossificans progressiva.

Ann N Y Acad Sci. 2006-4

[8]
Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP).

J Bone Miner Res. 2006-6

[9]
Purification and identification of a BMP-like factor from bovine serum.

Biochem Biophys Res Commun. 2006-7-7

[10]
A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.

Nat Genet. 2006-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索